Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Top Cited Papers
- 12 December 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 389 (10066), 255-265
- https://doi.org/10.1016/s0140-6736(16)32517-x
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In VivoThe Journal of Immunology, 2011
- The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In VivoThe Journal of Immunology, 2011
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell toleranceBlood, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directionsMucosal Immunology, 2009
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthmaBiochemical and Biophysical Research Communications, 2008
- Considerations for Second-Line Therapy of Non-Small Cell Lung CancerThe Oncologist, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007